The Antibody Society

📣 Calling all researchers and scientists! Keystone Symposia on Molecular & Cellular Biology is still accepting abstracts for short talks and scholarship applications for their upcoming conference, "𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗮𝘀 𝗗𝗿𝘂𝗴𝘀: 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗙𝗼𝗿𝗺𝗮𝘁𝘀, 𝗗𝗲𝘀𝗶𝗴𝗻, 𝗮𝗻𝗱 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴." Submit your abstract and scholarship application by 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟯, 𝟮𝟬𝟮𝟰, don’t miss out! 𝗩𝗶𝗲𝘄 𝗮𝗹𝗹 𝘁𝗵𝗲 𝗱𝗲𝘁𝗮𝗶𝗹𝘀 𝗵𝗲𝗿𝗲: https://lnkd.in/e6uQEa8d

Another one that is on our radar based on limited evidence so far... GSK posted details for a first in human study to evaluate safety, tolerability, PK and target engagement of GSK4528287 in healthy participants. The exclusion criteria includes significant allergies to humanized monoclonal antibodies and treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing. So...we guessing a humanized antibody? We're patient - we can wait for further disclosures. Due to start in November 2024, the study will enroll an estimated 48 participants. https://lnkd.in/eZXvEFep

Astellas Pharma Global Development, Inc. has posted details for a Phase 1 study of ASP1893 in adults with advanced CLDN6-positive solid tumors. In the terms used in the record: "ASP1893, the study treatment in this study, is thought to bind to CLDN6 and a protein found on certain immune cells. This process "tells" the immune system to attack the tumor." So... we're guessing a bispecific antibody that targets CLDN6 and CD3? Due to start in December 2024, the study will enroll an estimated 197 participants. https://lnkd.in/e2x3PJ8z

We look forward to seeing the new facility come online - should be a big advance for the field!

We look forward to watching this - thanks for sharing, Eva Smorodina!

🔔 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝗻𝗼𝘄 𝗼𝗽𝗲𝗻 𝗳𝗼𝗿 Lonza’𝘀 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘄𝗶𝘁𝗵 The Antibody Society! If you’re working on the development of monoclonal antibodies, ADCs, recombinant proteins, or cell and gene therapies, this is a webinar you won’t want to miss. Immunogenicity can pose a critical risk to biologics, including monoclonal antibodies, ADCs, recombinant proteins, and more. Understanding and mitigating these risks is key to ensuring patient safety and treatment efficacy. Dr. Noel Smith, Head of immunology at Lonza, will explore how the MAPPs assay can help identify regions within therapeutic proteins prone to HLA binding, aiding in the assessment of immunogenicity risk early in development. 𝐊𝐞𝐲 𝐬𝐞𝐬𝐬𝐢𝐨𝐧 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 : • Enhance lead selection & optimize candidates. • Investigate immunogenicity challenges. • Learn from a case study on an ADC that identified immunogenicity issues early in clinical trials. 🗓️ 𝐃𝐚𝐭𝐞: 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟏𝐬𝐭, 𝟐𝟎𝟐𝟒 | 🕒 𝐓𝐢𝐦𝐞: 𝟏𝟏:𝟎𝟎 𝐀𝐌 𝐄𝐓 𝐃𝐨𝐧’𝐭 𝐦𝐢𝐬𝐬 𝐨𝐮𝐭 - 𝐫𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰 𝐚𝐧𝐝 𝐬𝐞𝐜𝐮𝐫𝐞 𝐲𝐨𝐮𝐫 𝐬𝐩𝐨𝐭! 👉 https://lnkd.in/e2xK3wHp . . #Lonza #TheAntibodySociety #Immunogenicity #BiologicsDevelopment #Immunopeptidomics #MAPPs #Biotech #LifeSciences

In a recently published paper, Sanofi-based authors provide structural insights into epitope-paratope interactions of tusamitamab ravtansine, a monoclonal antibody targeting CEACAM5-expressing tumors. From the introduction and discussion: Here, we describe the high-resolution structure of the A3-B3 domains of CEACAM5 in complex with the antigen-binding fragment of tusamitamab (hereafter referred to as “tusa Fab”) by cryogenic electron microscopy (cryo-EM). Using hydrogen-deuterium exchange coupled with mass spectrometry (HDX-MS) and surface plasmon resonance (SPR) analysis of alanine variants, we further characterize the epitope-paratope interface between the A3-B3 domains of human CEACAM5 (hCEACAM5A3-B3) and tusa Fab. Taken together, these findings define the epitope-paratope interface between hCEACAM5 and a clinically relevant and highly specific antibody. The provided structural information was used for patient stratification in the clinical trials for the development of the drug. These studies may inform the future development of CEACAM5-directed antibody-based therapies for patients with cancer. #mabs https://lnkd.in/eF4tQ5nt

In business news, Aditum Bio and Leads Biolabs announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license agreement to develop LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody for autoimmune diseases. Aditum Bio will fund Oblenio Bio and the parties will collaborate to rapidly bring LBL-051 into clinical studies. Under the terms of the agreement, Leads Biolabs will grant Oblenio an exclusive option to develop, manufacture, and commercialize LBL-051 worldwide. Leads Biolabs is eligible to receive up to $35 million in upfront and near-term payments, $579 million in development, regulatory, and commercialization milestone payments, as well as royalties on sales. Additionally, Leads Biolabs is entitled to receive an equity stake in Oblenio Bio. https://lnkd.in/e8XKnUVe

The importance of validating antibody reagents is highlighted (again) in this interesting and informative Nature news feature. For more information, please check the Antibody Reagent Validation webinar series found on our YouTube channel. Many of the scientists mentioned in the article are featured in one of these webinars. https://lnkd.in/efXydTip

We agree - this is an excellent paper! Thanks for sharing, John Carpenter.